Drug class
Antihyperglycemic Hormone Analogs
The exact term "Antihyperglycemic Hormone Analogs" is an informal descriptive phrase or formulary category rather than a formal, standard FDA or WHO therapeutic drug class. Read more about Antihyperglycemic Hormone Analogs
0 drugs in this class 0 manufacturers
Drugs in Antihyperglycemic Hormone Analogs
No drugs are available
This class does not currently contain public drugs.
The exact term "Antihyperglycemic Hormone Analogs" is an informal descriptive phrase or formulary category rather than a formal, standard FDA or WHO therapeutic drug class.
In clinical pharmacology, this designation typically encompasses synthetic or recombinant analogues of endogenous peptide hormones that regulate blood glucose, most notably glucagon-like peptide-1 (GLP-1) receptor agonists, dual incretin agonists, and amylin analogues.
These agents function primarily by augmenting glucose-dependent insulin secretion, suppressing inappropriate postprandial glucagon release, and slowing gastric emptying.
Consequently, their primary therapeutic roles are centered on the management of type 2 diabetes mellitus and related metabolic conditions, including obesity.
-
jmcp.org
The exact term "Antihyperglycemic Hormone Analogs" is an informal descriptive phrase or formulary category rather than a formal, standard FDA or WHO therapeutic drug class
-
diabetesjournals.org
The exact term "Antihyperglycemic Hormone Analogs" is an informal descriptive phrase or formulary category rather than a formal, standard FDA or WHO therapeutic drug class These agents function primarily by augmenting glucose-dependent insulin secretion, suppressing inappropriate postprandial glucagon release, and slowing gastric emptying
-
researchgate.net
In clinical pharmacology, this designation typically encompasses synthetic or recombinant analogues of endogenous peptide hormones that regulate blood glucose, most notably glucagon-like peptide-1 (GLP-1) receptor agonists, dual incretin agonists, and amylin analogues Consequently, their primary therapeutic roles are centered on the management of type 2 diabetes mellitus and related metabolic conditions, including obesity
-
nih.gov
In clinical pharmacology, this designation typically encompasses synthetic or recombinant analogues of endogenous peptide hormones that regulate blood glucose, most notably glucagon-like peptide-1 (GLP-1) receptor agonists, dual incretin agonists, and amylin analogues
-
google.com
These agents function primarily by augmenting glucose-dependent insulin secretion, suppressing inappropriate postprandial glucagon release, and slowing gastric emptying
-
nih.gov
Consequently, their primary therapeutic roles are centered on the management of type 2 diabetes mellitus and related metabolic conditions, including obesity
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.